Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Personal Products Industry Analysis

UpdatedMar 09, 2026
DataAggregated Company Financials
Companies116
  • 7D-9.1%
  • 3M-2.7%
  • 1Y-11.1%
  • YTD-5.0%

Over the last 7 days, the Personal Products industry has dropped 9.1%, driven by Estée Lauder Companies declining 7.5%. In contrast, Oddity Tech has gained 15%. Overall the industry is down 11% in 12 months. Earnings are forecast to grow by 30% annually.

Industry Valuation and Performance

Has the U.S. Personal Products Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 09 Mar 2026US$86.4bUS$48.2bUS$789.9m23.4x109.4x1.8x
Wed, 04 Feb 2026US$96.0bUS$47.6bUS$349.9m22x274.4x2x
Fri, 02 Jan 2026US$89.4bUS$47.6bUS$351.1m22.6x254.7x1.9x
Sun, 30 Nov 2025US$86.3bUS$47.6bUS$357.6m23.2x241.4x1.8x
Tue, 28 Oct 2025US$89.5bUS$47.7bUS$290.5m21x308x1.9x
Thu, 25 Sep 2025US$91.7bUS$47.7bUS$298.4m21.5x307.2x1.9x
Sat, 23 Aug 2025US$98.8bUS$47.6bUS$304.6m21.8x324.3x2.1x
Mon, 21 Jul 2025US$100.8bUS$48.0bUS$109.7m18.3x918.6x2.1x
Wed, 18 Jun 2025US$96.9bUS$48.0bUS$108.2m17.5x895x2x
Fri, 16 May 2025US$92.3bUS$48.0bUS$83.9m20.8x1100.2x1.9x
Sun, 13 Apr 2025US$82.7bUS$48.7bUS$554.6m22.9x149.2x1.7x
Tue, 11 Mar 2025US$95.4bUS$49.0bUS$331.4m25.8x287.9x1.9x
Thu, 06 Feb 2025US$91.6bUS$49.0bUS$572.1m26.7x160.1x1.9x
Sat, 04 Jan 2025US$96.3bUS$49.3bUS$1.5b25.6x65.3x2x
Mon, 02 Dec 2024US$103.5bUS$49.3bUS$1.5b29.3x70.2x2.1x
Wed, 30 Oct 2024US$105.7bUS$49.5bUS$1.6b25.9x65.3x2.1x
Fri, 27 Sep 2024US$108.4bUS$49.5bUS$1.6b25.1x66.2x2.2x
Sun, 25 Aug 2024US$112.1bUS$49.5bUS$1.6b21.9x70.4x2.3x
Tue, 23 Jul 2024US$106.7bUS$49.0bUS$2.4b22.2x44.1x2.2x
Thu, 20 Jun 2024US$111.6bUS$49.0bUS$2.4b22.6x46x2.3x
Sat, 18 May 2024US$128.5bUS$48.8bUS$2.5b21.6x52.4x2.6x
Mon, 15 Apr 2024US$120.8bUS$48.8bUS$2.5b25.3x47.6x2.5x
Wed, 13 Mar 2024US$134.5bUS$49.1bUS$2.4b28.7x55.6x2.7x
Fri, 09 Feb 2024US$129.3bUS$49.2bUS$2.6b25.5x50.3x2.6x
Sun, 07 Jan 2024US$124.8bUS$49.9bUS$2.6b25.1x47.4x2.5x
Tue, 05 Dec 2023US$119.7bUS$49.9bUS$2.6b26.8x46x2.4x
Thu, 02 Nov 2023US$100.6bUS$49.7bUS$2.8b23.9x35.5x2x
Sat, 30 Sep 2023US$121.5bUS$50.0bUS$3.3b23.4x36.9x2.4x
Mon, 28 Aug 2023US$132.2bUS$50.0bUS$3.3b20.1x40.4x2.6x
Wed, 26 Jul 2023US$148.5bUS$49.8bUS$3.1b25.6x48.5x3x
Fri, 23 Jun 2023US$153.3bUS$49.3bUS$3.1b23x48.9x3.1x
Sun, 21 May 2023US$154.5bUS$49.0bUS$3.3b22.9x46.7x3.2x
Tue, 18 Apr 2023US$124.6bUS$34.5bUS$1.7b17.8x74.3x3.6x
Thu, 16 Mar 2023US$116.1bUS$34.8bUS$1.5b16.8x77.6x3.3x
Price to Earnings Ratio

77.6x


Total Market Cap: US$116.1bTotal Earnings: US$1.5bTotal Revenue: US$34.8bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Personal Products Industry Price to Earnings3Y Average 167x202420252026
Current Industry PE
  • Investors are pessimistic on the American Personal Products industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 109x which is lower than its 3-year average PE of 167x.
  • The 3-year average PS ratio of 2.3x is higher than the industry's current PS ratio of 1.8x.
Past Earnings Growth
  • The earnings for companies in the Personal Products industry have declined 19% per year over the last three years.
  • Meanwhile revenues for these companies have grown 11% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Consumer Staples industry?

US Market-2.17%
Consumer Staples-4.45%
Personal Products-9.10%
Personal Products-9.10%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ODD Oddity TechUS$14.1915.3%
+US$108.0m		-66.5%PE7.4x
ELF e.l.f. BeautyUS$82.441.0%
+US$47.2m		11.3%PE46.8x
HNST Honest CompanyUS$2.9311.4%
+US$33.7m		-37.8%PS0.9x
SKIN Beauty HealthUS$1.145.6%
+US$7.7m		-11.3%PS0.5x
NAGE Niagen BioscienceUS$5.061.4%
+US$7.0m		-35.8%PE23.4x

Latest News

HNST
US$2.93
Honest Company
7D
11.4%
1Y
-37.8%
COTY
US$2.37
Coty
7D
-4.0%
1Y
-60.6%

COTY: Gucci License Exit And New CEO Will Test Fragrance Reliance

The analyst price target on Coty has been reduced by about $0.50, as analysts factor in lower fair value estimates and more moderate revenue growth and margin assumptions, even as they apply a slightly lower discount rate and a modestly higher future P/E multiple. Analyst Commentary Recent Street research on Coty has leaned cautious, with several bearish analysts trimming their price targets in relatively quick succession.
SKIN
US$1.14
Beauty Health
7D
5.6%
1Y
-11.3%
NAGE
US$5.06
Niagen Bioscience
7D
1.4%
1Y
-35.8%

NAGE: Core Demand And Injectables Outlook Will Support Future Upside

Analysts have trimmed their 12 month price target on Niagen Bioscience from $16.04 to $13.60, citing updated models that reflect steady demand in the core business, potential upside in injectables, adjustments to revenue growth and profit margin assumptions, and a lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to steady demand in the core business as a key support for current valuation, suggesting the updated models still see the existing portfolio as a meaningful earnings driver.
OLPX
US$1.35
Olaplex Holdings
7D
-11.5%
1Y
-14.9%

OLPX: Henkel Takeover Talks And Refined Earnings Profile Will Reprice Shares

Analysts have lifted their price target on Olaplex Holdings to $3.59, citing updated assumptions around a slightly lower discount rate, more measured revenue growth, a modestly higher profit margin profile, and a recalibrated future P/E multiple informed by recent research from Barclays and Jefferies. Analyst Commentary Bullish analysts are framing the latest price target move to US$3.59 as part of a more constructive view on Olaplex Holdings, built around refined assumptions on discount rates, revenue pacing, profit margins, and future valuation multiples informed by recent research.
EL
US$92.72
Estée Lauder Companies
7D
-7.5%
1Y
28.7%
LFVN
US$4.88
LifeVantage
7D
8.0%
1Y
-69.0%

LFVN: Buybacks And Margin Improvement Will Support Future Upside Potential

Narrative Update on LifeVantage Analysts have lowered their price target on LifeVantage by $7, citing updated assumptions for the discount rate, revenue trajectory, profit margin and future P/E, which together indicate a more cautious valuation framework. Analyst Commentary Analysts describe the lower price target as a reset of expectations rather than a change in the core story, anchoring their work in updated views on discount rate, revenue trajectory, profit margin and future P/E.
MED
US$10.77
Medifast
7D
3.2%
1Y
-28.4%

MED: Future Leadership Shift Will Align With New Metabolic Health System

Analysts have modestly reduced their price target on Medifast, citing a slightly lower discount rate, a small improvement in projected profit margin, and a shift to a lower future P/E assumption. Together, these factors point to a more cautious valuation framework in dollar terms.
BRBR
US$17.39
BellRing Brands
7D
-4.2%
1Y
-73.4%

BRBR: Future Returns Will Depend On Execution In A Tougher Category

The analyst price target for BellRing Brands has been reset from $26 to $22 as analysts factor in lower assumed revenue growth, slimmer profit margins, and a reduced future P/E multiple in a more competitive category backdrop. Analyst Commentary Recent Street research on BellRing Brands reflects a clear reset in expectations, with multiple bearish analysts trimming price targets and stressing a tougher setup for execution and growth.
ODD
US$14.19
Oddity Tech
7D
15.3%
1Y
-66.5%

ODD: Corrective Actions On Ad Disruption Will Restore Confidence Over Time

Analysts have sharply cut their price targets on Oddity Tech into a roughly $10 to $30 range from prior levels as high as $80, citing higher customer acquisition costs tied to disruptions at a major advertising partner and weaker near term visibility on growth and margins. Analyst Commentary Recent research reports cluster around a similar theme for Oddity Tech, with most firms cutting ratings and bringing price targets into a lower $10 to $30 range after the Q4 print and Q1 outlook tied to issues with a major advertising partner.
IPAR
US$94.58
Interparfums
7D
-4.6%
1Y
-25.6%
ELF
US$82.44
e.l.f. Beauty
7D
1.0%
1Y
11.3%

ELF: Fair Outlook Weighs Weekly Sales Strength Against Margin And P E Risks

Analysts have made only a modest tweak to their blended price target for e.l.f. Beauty, with mixed $10 and $7 cuts alongside $4 and $6 raises and fresh bullish coverage, reflecting updated views on its revenue growth, margins, and future P/E assumptions. Analyst Commentary Recent research on e.l.f. Beauty shows a split in sentiment, with some firms lifting price targets or starting coverage on a bullish footing, while others are trimming their expectations.
EPC
US$21.13
Edgewell Personal Care
7D
-4.9%
1Y
-34.3%

EPC: Share Repurchases And 2026 Earnings Reset Will Guide Balanced Return Potential

Analysts kept their $21.00 price target for Edgewell Personal Care unchanged, citing small refinements to discount rate, long run revenue trends and profit margin assumptions, along with a slightly lower future P/E multiple as reasons for maintaining their overall valuation view. What's in the News Completion of a long running share repurchase program, with 9,773,306 shares bought back for $356.96 million under the buyback announced on February 8, 2018 (Key Developments) Update that from October 1, 2025 to November 13, 2025, the company did not repurchase additional shares under the 2018 buyback program, with 0 shares and $0 million recorded for that period (Key Developments) Launch of a new share repurchase authorization on November 13, 2025, with no shares repurchased and $0 million deployed from November 13, 2025 to December 31, 2025 under this newer program (Key Developments) Revision of full fiscal year 2026 earnings guidance, reflecting removal of the Feminine Care business and presenting outlook on a continuing operations basis, with prior periods recast for comparability (Key Developments) Updated 2026 outlook assumptions, including expected reported net sales change in a range of approximately 0.5% to 3.5%, organic net sales in a range of a 1.0% decline to a 2% increase, and GAAP EPS in a range of $0.55 to $0.95 including restructuring, Sun Care reformulation and other costs (Key Developments) Valuation Changes Fair Value: The $21.00 fair value estimate is unchanged, so the overall valuation anchor remains the same.
HLF
US$15.47
Herbalife
7D
-19.6%
1Y
73.6%
KVUE
US$18.39
Kenvue
7D
-2.6%
1Y
-23.1%

KVUE: Future Returns Will Reflect Legal Outcomes And Kimberly-Clark Transaction Execution

The analyst price target for Kenvue has increased by about $0.75 to $19.67 as analysts factor in recent top and bottom line beats, segment growth, and updated P/E and cash flow assumptions. These updates are reflected in slightly higher fair value, revenue growth, and profit margin inputs.
DSY
US$3.79
Big Tree Cloud Holdings
7D
25.5%
1Y
-85.0%